The Pharma Data

NOVEMBER 9, 2020

About Tezepelumab Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants, and other environmental insults. Amgen will record sales in the U.S. Outside the U.S.,

Trials 52

Trials Production Sales Manufacturing 52

Roots Analysis

NOVEMBER 3, 2023

NAD + is involved in a wide range of cellular processes, including energy metabolism, DNA repair, and gene expression. There are several types of NAMPT inhibitors, including small molecules, peptides, and antibodies. NAMPT inhibitors work by blocking the activity of NAMPT, which in turn reduces the production of NAD +.

Development 40

Development Drugs Trials FDA Approval 40

pharmaphorum

JANUARY 10, 2023

Xork is designed as a pre-treatment to overcome one of the key limitations to adeno-associated virus (AAV) based gene therapies like AT845, namely that some patients have existing antibodies against the AAV vector that interfere with the treatment. The post Astellas licenses companion drug for Pompe gene therapy appeared first on.

Gene Therapy 119

Gene Therapy Gene Licensing Licensing 119

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Genetics 130

Genetics Gene Expression DNA Antibody 130

XTalks

MARCH 22, 2021

The biotech acquisition deal includes Five Prime’s prime asset bemarituzumab, which is a first-in-class anti-FGFR2b antibody. The antibody accrued promising data in a randomized, placebo-controlled Phase II study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer, and is now being prepared for Phase III trials.

Life Science 110

Life Science Development Marketing Gene Expression 110

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells.

Trials 59

Trials Gene Silencing RNA Gene Expression 59

Roots Analysis

OCTOBER 22, 2023

Coding RNAs include messenger RNA (mRNA) and short interfering RNA (siRNA), which encode proteins and silence gene expression, respectively. RNA interference (RNAi) Therapeutics : Fundamentally, RNAi is a natural process of post-transcriptional gene silencing, involving short strands of nucleic acids.

RNA 40

RNA Protein Genetics Gene Expression 40

The Pharma Data

OCTOBER 15, 2020

On the clinical side, cell and gene therapies must find places where small molecules, antibodies or other traditional approaches may not be the best option. Small molecule and antibody therapies haven’t been able to do that.”. For example, “The era of transplant medicine is unfolding before us,” Culley said.

Manufacturing 52

Manufacturing Gene Therapy Gene Gene Expression 52

The Pharma Data

JULY 8, 2021

“We are proud to advance an innovative, first-in-class monoclonal antibody that targets the top of the inflammatory cascade and represents a potentially transformative treatment option for a broad population of patients with severe asthma. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma.

Allergies 52

Allergies Trials In-Vivo Medicine 52

The Pharma Data

AUGUST 3, 2021

HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression. Istodax ® (romidepsin) for injection is an epigenetic therapy and a member of a class of cancer drugs known as histone deacetylase (HDAC) inhibitors.

In-Vitro 52

In-Vitro Nurses Gene Expression Medicine 52

Delveinsight

JULY 30, 2020

Roche bets USD 120 Million on UCB’s anti-tau Alzheimer’s antibody. The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB’s anti-tau antibody development. Omega’s platform is designed to adjust gene expression to healthy levels rather than switching genes on and off.

Genome 52

Genome Genomics Antibody Gene 52

The Pharma Data

DECEMBER 27, 2020

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. The drug is a humanized IgG4 monoclonal antibody that blocks CCR5 and is being developed for COVID-19, HIV and metastatic triple-negative breast cancer.

Trials 52

Trials Antibody Gene Therapy Gene 52

XTalks

DECEMBER 24, 2020

Most antibody drugs and vaccines have been developed to target parts of the spike protein. These include remdesivir, baricitinib, dexamethasone and three antibody drugs. Antibody drugs were also developed as targeted COVID-19 treatments. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111